Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity

Alexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, Willem H. Kruit, Cornelis J. Punt, Reinhard Dummer, François Salès, Ulrich Keilholz, Gaetan De Schaetzen, Alessandro Testori

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background We report on the long term outcome of the EORTC 18952 adjuvant interferon (IFN) trial in 1388 resected stage IIB/III melanoma patients and identify key predictive factors for outcome. Methods We analysed outcome of the EORTC 18952 trial (4 weeks of IFN, 10 MU, 5 times/week for 4 weeks followed by 12 months IFN at 10 MU, 3 times/week versus followed by 24 months IFN at 5 MU 3 times/week versus observation) regarding relapse-free survival (RFS), distant metastasis-free interval/survival (DMFI/DMFS), and overall survival (OS), and analysed potential predictive factors of outcome. Findings At a median follow-up of 11 years, the comparison of IFN 13 months versus IFN 25 months versus observation yielded estimated hazard ratios (HR) for RFS of 0.94 versus 0.84 (p = 0.06); for DMFI 0.95 versus 0.82 (p = 0.027); for DMFS 0.95 versus 0.84 (p = 0.07); and for OS 0·95 versus 0.84 (p = 0.08), respectively. The impact of treatment was greatest in the ulceration group, whereas in patients with non-ulcerated primaries the impact was null (HR ≥ 1.0). In patients with ulcerated melanoma the HR for IFN 13 months versus 25 months versus observation were for: RFS 0.82 (p = 0.16) versus 0.61 (p = 0.0008); DMFS 0.76 (p = 0.06) versus 0.57 (p = 0.0003); OS 0.80 (p = 0.13) versus 0.59 (p = 0.0007). In stage IIB/III-N1 (microscopic nodal involvement only) patients with ulcerated melanoma the HR estimates were for: RFS 0.85 versus 0.62; DMFS 0.80 versus 0.56; OS 0.77 versus 0.54. Conclusions This long term report of the EORTC 18952 trial demonstrates the superiority of the 25-month IFN schedule and defines ulceration of the primary as the overriding predictive factor for IFN-sensitivity.

Original languageEnglish
Pages (from-to)111-121
Number of pages11
JournalEuropean Journal of Cancer
Volume55
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

interferon alfa-2b
Melanoma
Observation
Skin
Survival
Recurrence
Therapeutics

Keywords

  • Adjuvant
  • Interferon
  • Melanoma
  • Predictive factors
  • Randomised trial
  • Ulceration

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation : Ulceration of primary is key determinant for IFN-sensitivity. / Eggermont, Alexander M M; Suciu, Stefan; Rutkowski, Piotr; Kruit, Willem H.; Punt, Cornelis J.; Dummer, Reinhard; Salès, François; Keilholz, Ulrich; De Schaetzen, Gaetan; Testori, Alessandro.

In: European Journal of Cancer, Vol. 55, 01.03.2016, p. 111-121.

Research output: Contribution to journalArticle

Eggermont, Alexander M M ; Suciu, Stefan ; Rutkowski, Piotr ; Kruit, Willem H. ; Punt, Cornelis J. ; Dummer, Reinhard ; Salès, François ; Keilholz, Ulrich ; De Schaetzen, Gaetan ; Testori, Alessandro. / Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation : Ulceration of primary is key determinant for IFN-sensitivity. In: European Journal of Cancer. 2016 ; Vol. 55. pp. 111-121.
@article{6fb5a78e58d84f16a1f9c83ceabf3d37,
title = "Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity",
abstract = "Background We report on the long term outcome of the EORTC 18952 adjuvant interferon (IFN) trial in 1388 resected stage IIB/III melanoma patients and identify key predictive factors for outcome. Methods We analysed outcome of the EORTC 18952 trial (4 weeks of IFN, 10 MU, 5 times/week for 4 weeks followed by 12 months IFN at 10 MU, 3 times/week versus followed by 24 months IFN at 5 MU 3 times/week versus observation) regarding relapse-free survival (RFS), distant metastasis-free interval/survival (DMFI/DMFS), and overall survival (OS), and analysed potential predictive factors of outcome. Findings At a median follow-up of 11 years, the comparison of IFN 13 months versus IFN 25 months versus observation yielded estimated hazard ratios (HR) for RFS of 0.94 versus 0.84 (p = 0.06); for DMFI 0.95 versus 0.82 (p = 0.027); for DMFS 0.95 versus 0.84 (p = 0.07); and for OS 0·95 versus 0.84 (p = 0.08), respectively. The impact of treatment was greatest in the ulceration group, whereas in patients with non-ulcerated primaries the impact was null (HR ≥ 1.0). In patients with ulcerated melanoma the HR for IFN 13 months versus 25 months versus observation were for: RFS 0.82 (p = 0.16) versus 0.61 (p = 0.0008); DMFS 0.76 (p = 0.06) versus 0.57 (p = 0.0003); OS 0.80 (p = 0.13) versus 0.59 (p = 0.0007). In stage IIB/III-N1 (microscopic nodal involvement only) patients with ulcerated melanoma the HR estimates were for: RFS 0.85 versus 0.62; DMFS 0.80 versus 0.56; OS 0.77 versus 0.54. Conclusions This long term report of the EORTC 18952 trial demonstrates the superiority of the 25-month IFN schedule and defines ulceration of the primary as the overriding predictive factor for IFN-sensitivity.",
keywords = "Adjuvant, Interferon, Melanoma, Predictive factors, Randomised trial, Ulceration",
author = "Eggermont, {Alexander M M} and Stefan Suciu and Piotr Rutkowski and Kruit, {Willem H.} and Punt, {Cornelis J.} and Reinhard Dummer and Fran{\cc}ois Sal{\`e}s and Ulrich Keilholz and {De Schaetzen}, Gaetan and Alessandro Testori",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2015.11.014",
language = "English",
volume = "55",
pages = "111--121",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation

T2 - Ulceration of primary is key determinant for IFN-sensitivity

AU - Eggermont, Alexander M M

AU - Suciu, Stefan

AU - Rutkowski, Piotr

AU - Kruit, Willem H.

AU - Punt, Cornelis J.

AU - Dummer, Reinhard

AU - Salès, François

AU - Keilholz, Ulrich

AU - De Schaetzen, Gaetan

AU - Testori, Alessandro

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background We report on the long term outcome of the EORTC 18952 adjuvant interferon (IFN) trial in 1388 resected stage IIB/III melanoma patients and identify key predictive factors for outcome. Methods We analysed outcome of the EORTC 18952 trial (4 weeks of IFN, 10 MU, 5 times/week for 4 weeks followed by 12 months IFN at 10 MU, 3 times/week versus followed by 24 months IFN at 5 MU 3 times/week versus observation) regarding relapse-free survival (RFS), distant metastasis-free interval/survival (DMFI/DMFS), and overall survival (OS), and analysed potential predictive factors of outcome. Findings At a median follow-up of 11 years, the comparison of IFN 13 months versus IFN 25 months versus observation yielded estimated hazard ratios (HR) for RFS of 0.94 versus 0.84 (p = 0.06); for DMFI 0.95 versus 0.82 (p = 0.027); for DMFS 0.95 versus 0.84 (p = 0.07); and for OS 0·95 versus 0.84 (p = 0.08), respectively. The impact of treatment was greatest in the ulceration group, whereas in patients with non-ulcerated primaries the impact was null (HR ≥ 1.0). In patients with ulcerated melanoma the HR for IFN 13 months versus 25 months versus observation were for: RFS 0.82 (p = 0.16) versus 0.61 (p = 0.0008); DMFS 0.76 (p = 0.06) versus 0.57 (p = 0.0003); OS 0.80 (p = 0.13) versus 0.59 (p = 0.0007). In stage IIB/III-N1 (microscopic nodal involvement only) patients with ulcerated melanoma the HR estimates were for: RFS 0.85 versus 0.62; DMFS 0.80 versus 0.56; OS 0.77 versus 0.54. Conclusions This long term report of the EORTC 18952 trial demonstrates the superiority of the 25-month IFN schedule and defines ulceration of the primary as the overriding predictive factor for IFN-sensitivity.

AB - Background We report on the long term outcome of the EORTC 18952 adjuvant interferon (IFN) trial in 1388 resected stage IIB/III melanoma patients and identify key predictive factors for outcome. Methods We analysed outcome of the EORTC 18952 trial (4 weeks of IFN, 10 MU, 5 times/week for 4 weeks followed by 12 months IFN at 10 MU, 3 times/week versus followed by 24 months IFN at 5 MU 3 times/week versus observation) regarding relapse-free survival (RFS), distant metastasis-free interval/survival (DMFI/DMFS), and overall survival (OS), and analysed potential predictive factors of outcome. Findings At a median follow-up of 11 years, the comparison of IFN 13 months versus IFN 25 months versus observation yielded estimated hazard ratios (HR) for RFS of 0.94 versus 0.84 (p = 0.06); for DMFI 0.95 versus 0.82 (p = 0.027); for DMFS 0.95 versus 0.84 (p = 0.07); and for OS 0·95 versus 0.84 (p = 0.08), respectively. The impact of treatment was greatest in the ulceration group, whereas in patients with non-ulcerated primaries the impact was null (HR ≥ 1.0). In patients with ulcerated melanoma the HR for IFN 13 months versus 25 months versus observation were for: RFS 0.82 (p = 0.16) versus 0.61 (p = 0.0008); DMFS 0.76 (p = 0.06) versus 0.57 (p = 0.0003); OS 0.80 (p = 0.13) versus 0.59 (p = 0.0007). In stage IIB/III-N1 (microscopic nodal involvement only) patients with ulcerated melanoma the HR estimates were for: RFS 0.85 versus 0.62; DMFS 0.80 versus 0.56; OS 0.77 versus 0.54. Conclusions This long term report of the EORTC 18952 trial demonstrates the superiority of the 25-month IFN schedule and defines ulceration of the primary as the overriding predictive factor for IFN-sensitivity.

KW - Adjuvant

KW - Interferon

KW - Melanoma

KW - Predictive factors

KW - Randomised trial

KW - Ulceration

UR - http://www.scopus.com/inward/record.url?scp=84954458766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954458766&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.11.014

DO - 10.1016/j.ejca.2015.11.014

M3 - Article

C2 - 26790144

AN - SCOPUS:84954458766

VL - 55

SP - 111

EP - 121

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -